NASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Forecast, Price & News $20.47 +0.30 (+1.49%) (As of 06/2/2023 06:55 PM ET) Add Compare Share Share Today's Range$19.99▼$20.5650-Day Range$19.35▼$22.2652-Week Range$14.69▼$29.86Volume1.13 million shsAverage Volume849,037 shsMarket Capitalization$1.41 billionP/E RatioN/ADividend YieldN/APrice Target$33.86 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Syndax Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside65.4% Upside$33.86 Price TargetShort InterestBearish9.29% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.73Based on 6 Articles This WeekInsider TradingSelling Shares$3.35 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.98) to ($2.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector146th out of 980 stocksPharmaceutical Preparations Industry64th out of 485 stocks 3.5 Analyst's Opinion Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.86, Syndax Pharmaceuticals has a forecasted upside of 65.4% from its current price of $20.47.Amount of Analyst CoverageSyndax Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.29% of the outstanding shares of Syndax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently decreased by 1.99%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Syndax Pharmaceuticals is -1.12. Previous Next 3.7 News and Social Media Coverage News SentimentSyndax Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Syndax Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest4 people have searched for SNDX on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,354,684.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Syndax Pharmaceuticals is held by insiders.Percentage Held by Institutions99.11% of the stock of Syndax Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($2.98) to ($2.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -8.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -8.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Syndax Pharmaceuticals (NASDAQ:SNDX) StockSyndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.Read More Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SNDX Stock News HeadlinesJune 5, 2023 | americanbankingnews.comAnalysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $33.86June 3, 2023 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Sees Strong Trading VolumeJune 5, 2023 | Edge On The Street (Ad)AI industry Is Exploding! New Breakthrough Expected this SummerBill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.May 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Premier (PINC)May 13, 2023 | americanbankingnews.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Briggs Morrison Sells 52,855 SharesMay 12, 2023 | msn.comCitigroup Maintains Syndax Pharmaceuticals (SNDX) Buy RecommendationMay 11, 2023 | markets.businessinsider.comSyndax Pharmaceuticals (SNDX) Receives a Buy from Goldman SachsMay 11, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Syndax Pharmaceuticals, Inc. Decreased by B. Riley (NASDAQ:SNDX)June 5, 2023 | Edge On The Street (Ad)AI industry Is Exploding! New Breakthrough Expected this SummerBill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.May 11, 2023 | americanbankingnews.comEquities Analysts Issue Forecasts for Syndax Pharmaceuticals, Inc.'s Q2 2023 Earnings (NASDAQ:SNDX)May 11, 2023 | americanbankingnews.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $33.57 Consensus Price Target from BrokeragesMay 11, 2023 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up After Analyst UpgradeMay 10, 2023 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) PT Lowered to $31.00May 9, 2023 | msn.comHC Wainwright & Co. Maintains Syndax Pharmaceuticals (SNDX) Buy RecommendationMay 9, 2023 | finance.yahoo.comQ1 2023 Syndax Pharmaceuticals Inc Earnings CallMay 9, 2023 | finanznachrichten.deSyndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business UpdateMay 9, 2023 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Increased to $36.00 by Analysts at HC WainwrightMay 8, 2023 | seekingalpha.comSyndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call TranscriptMay 8, 2023 | finance.yahoo.comSyndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business UpdateMay 7, 2023 | americanbankingnews.comSyndax Pharmaceuticals (SNDX) Set to Announce Earnings on MondayMay 5, 2023 | msn.comSyndax Pharmaceuticals Earnings PreviewMay 1, 2023 | finance.yahoo.comSyndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023April 26, 2023 | markets.businessinsider.comGoldman Sachs Remains a Buy on Syndax Pharmaceuticals (SNDX)April 17, 2023 | americanbankingnews.comStockNews.com Upgrades Syndax Pharmaceuticals (NASDAQ:SNDX) to "Sell"April 13, 2023 | americanbankingnews.comInsider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Sells 52,855 Shares of StockApril 12, 2023 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 3.6%March 30, 2023 | finance.yahoo.comSyndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and DevelopmentSee More Headlines SNDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNDX Company Calendar Last Earnings5/08/2023Today6/05/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNDX CUSIPN/A CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees59Year FoundedN/APrice Target and Rating Average Stock Price Forecast$33.86 High Stock Price Forecast$37.00 Low Stock Price Forecast$31.00 Forecasted Upside/Downside+65.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-149,340,000.00 Net MarginsN/A Pretax Margin-11.02% Return on Equity-38.25% Return on Assets-35.58% Debt Debt-to-Equity RatioN/A Current Ratio18.61 Quick Ratio18.61 Sales & Book Value Annual Sales$139.71 million Price / Sales10.08 Cash FlowN/A Price / Cash FlowN/A Book Value$7.76 per share Price / Book2.64Miscellaneous Outstanding Shares68,820,000Free Float65,586,000Market Cap$1.41 billion OptionableOptionable Beta1.13 Key ExecutivesMichael A. MetzgerChief Executive Officer & DirectorNeil GallagherPresident, Head-Research & DevelopmentKeith Alan GoldanTreasurer, Chief Financial & Accounting OfficerPeter OrdentlichChief Scientific OfficerBriggs W. MorrisonDirectorKey CompetitorsTaro Pharmaceutical IndustriesNYSE:TAROAgios PharmaceuticalsNASDAQ:AGIOGemini TherapeuticsNASDAQ:GMTXDynavax TechnologiesNASDAQ:DVAXAurinia PharmaceuticalsNASDAQ:AUPHView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 10,943 shares on 6/1/2023Ownership: 0.016%JPMorgan Chase & Co.Bought 10,959 shares on 5/18/2023Ownership: 0.798%New York State Common Retirement FundSold 7,689 shares on 5/18/2023Ownership: 0.043%AQR Capital Management LLCSold 1,947 shares on 5/16/2023Ownership: 0.034%Balyasny Asset Management L.P.Bought 19,102 shares on 5/16/2023Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions SNDX Stock - Frequently Asked Questions Should I buy or sell Syndax Pharmaceuticals stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNDX shares. View SNDX analyst ratings or view top-rated stocks. What is Syndax Pharmaceuticals' stock price forecast for 2023? 6 Wall Street analysts have issued twelve-month price targets for Syndax Pharmaceuticals' stock. Their SNDX share price forecasts range from $31.00 to $37.00. On average, they anticipate the company's share price to reach $33.86 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price. View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts. How have SNDX shares performed in 2023? Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of the year. Since then, SNDX shares have decreased by 19.6% and is now trading at $20.47. View the best growth stocks for 2023 here. When is Syndax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our SNDX earnings forecast. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its earnings results on Monday, May, 8th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.02. What ETFs hold Syndax Pharmaceuticals' stock? ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV). What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU). When did Syndax Pharmaceuticals IPO? (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. What is Syndax Pharmaceuticals' stock symbol? Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX." Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (10.22%), BlackRock Inc. (7.15%), State Street Corp (5.62%), Jennison Associates LLC (3.53%), BVF Inc. IL (3.11%) and Dimensional Fund Advisors LP (1.93%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich and Pierre Legault. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Syndax Pharmaceuticals' stock price today? One share of SNDX stock can currently be purchased for approximately $20.47. How much money does Syndax Pharmaceuticals make? Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $1.41 billion and generates $139.71 million in revenue each year. The company earns $-149,340,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. How can I contact Syndax Pharmaceuticals? Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420. This page (NASDAQ:SNDX) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.